Novartis AG (LTS:0QM7) Total Operating Expense: CHF20,313.34 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Novartis AG Total Operating Expense?

Novartis AG LTS:0QM7 81 Total Operating Expense is CHF20,313.34 Mil as of Mar. 2026. GuruFocus rates LTS:0QM7 with a GF Score™ of 81/100. The stock has 7 warning signs investors should review.

Novartis AG's Total Operating Expense for the three months ended in Mar. 2026 was CHF4,589.96 Mil. Novartis AG's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was CHF20,313.34 Mil.

Novartis AG Total Operating Expense Related Terms

Novartis AG Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Novartis AG's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG Total Operating Expense Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20,430.54 22,295.98 21,117.55 21,711.35 20,186.27

Novartis AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,063.03 5,407.78 5,029.76 5,285.84 4,589.96

Novartis AG Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF20,313.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of CHF20,313.34 Mil mean?
Novartis AG (LTS:0QM7) has a Total Operating Expense of CHF20,313.34 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Novartis AG and its competitors.
Is Novartis AG's Total Operating Expense too high?
Novartis AG's current Total Operating Expense is CHF20,313.34 Mil. Overall, Novartis AG has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Total Operating Expense compare to LLY and JNJ?
Novartis AG's Total Operating Expense of CHF20,313.34 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Novartis AG and its competitors. Novartis AG's current Total Operating Expense is CHF20,313.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Novartis AG (LTS:0QM7) has a current Total Operating Expense of CHF20,313.34 Mil. The current Total Operating Expense is CHF20,313.34 Mil. Novartis AG's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Novartis AG (LTS:0QM7), the current Total Operating Expense is CHF20,313.34 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.